Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Top Page
Abeona Therapeutics
(NASDAQ:ABEO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.50
▼(-8.35% Downside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by weak financial performance—large ongoing operating losses and heavy cash burn despite improved balance-sheet strength. Technicals are mixed with a weaker intermediate/longer-term trend, while earnings-call updates and recent events provide moderate support through improving reimbursement and early launch progress, tempered by execution risk in scaling patient throughput.
Positive Factors
Strong cash position
The $191.4M liquidity cushion from the priority review voucher proceeds materially extends runway for commercialization activities, QTC onboarding, and manufacturing scale-up. This reduces near-term financing pressure and gives management time to execute patient ramp and payer workflows.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means the business remains dependent on external capital unless product revenue ramps quickly. Even with current cash, continued high burn raises refinancing or dilution risk if patient throughput or reimbursement realization is slower than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position
The $191.4M liquidity cushion from the priority review voucher proceeds materially extends runway for commercialization activities, QTC onboarding, and manufacturing scale-up. This reduces near-term financing pressure and gives management time to execute patient ramp and payer workflows.
Read all positive factors
Abeona Therapeutics (ABEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$280.11M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)3.9
Beta (1Y)1.07
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding57,049,023
10 Day Avg. Volume865,587
30 Day Avg. Volume1,286,846
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue38.94
Enterprise Value/Gross Profit147.94
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$21.40Price Target Upside335.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$65.61M
Abeona Therapeutics Business Overview & Revenue Model
Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical...
How the Company Makes Money
Abeona Therapeutics does not have consistently disclosed, product-based commercial revenue as a primary earnings source; as a clinical-stage biotech, it has historically funded operations mainly through financing activities (e.g., equity offerings...
Abeona Therapeutics Earnings Call Summary
Earnings Call Date:Mar 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Positive
The call highlighted several strong positives: a transformative one-time gain from the priority review voucher that produced a substantial net income swing and strengthened cash; regulatory and reimbursement progress (J-code and broad payer coverage); growing patient identification (50 to +100); and an on-track manufacturing capacity expansion to ~10 patients/month. However, meaningful operational risks and near-term commercialization challenges remain: an earlier sterility-related batch failure and launch delay, slow initial patient throughput (only two treated to date), a lengthy 4–5 month timeline from consult to treatment, and sharply higher SG&A as the company transitions to commercial operations. While early commercial traction is improving and the company has sufficient liquidity, execution of QTC onboarding and consistent patient cadence are critical to meet profitability and scale expectations.Positive Updates
Major Non-Operating Gain from Priority Review Voucher Sale
Recorded a $1,524,000,000 gain on sale of a rare pediatric disease priority review voucher (sale completed June 2025), materially improving 2025 profitability and liquidity.
Negative Updates
Launch Delay and Manufacturing Batch Failure
Launch was delayed to Q4 2025 to optimize an FDA-mandated sterility test; an August production batch was not released due to technical challenges with the rapid sterility lot release assay, and associated costs were recorded in 2025 cost of sales.
Read all updates
Q4-2025 Updates
Positive
Negative
Major Non-Operating Gain from Priority Review Voucher Sale
Recorded a $1,524,000,000 gain on sale of a rare pediatric disease priority review voucher (sale completed June 2025), materially improving 2025 profitability and liquidity.
Read all positive updates
Company Guidance
The call guided that ZivaSkin—approved April 2025 but launched in Q4 2025 after a sterility-test delay—has treated two commercial patients since launch (first treated in December), with three additional patients biopsied and more biopsies expected this month; identified eligible patients have grown from nearly 50 to >100. Operationally Abeona has four qualified treatment centers (two actively treating, two scheduling), is onboarding five more with a goal of ≥7 QTCs by year-end, and expects per‑site run rates of ~1–2 patients/month (some sites up to 3), a facility capacity currently ~6 patients/month ramping to 10/month by H2; the patient journey from consult to treatment averages ~4–5 months (25 days manufacturing). Market access: major commercial payers (UnitedHealthcare, Cigna, Aetna, Anthem and most BCBS) cover ~80% of commercially covered lives, Medicaid baseline coverage in all 50 states, and a permanent HCPCS J‑code effective 1/1/2026. Financially, 2025 revenue was $5.8M (license/other $3.4M, net product $2.4M), cost of sales $1.5M, R&D $26.8M, SG&A $65.0M, a $1.524B gain on sale of a priority review voucher, net income $71.2M (EPS $1.034 basic/$1.10 diluted), and $191.4M cash/short‑term investments; management expects gross margins to improve with scale and estimates company‑level profitability once run rates exceed ~3–3.5 patients/month (roughly the ~$100M annual burn crossover).Abeona Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
67
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.82M | 0.00 | 3.50M | 1.41M | 3.00M |
| Gross Profit | 4.29M | -2.91M | 1.90M | 964.00K | 3.00M |
| EBITDA | -85.89M | -56.62M | -50.57M | -34.38M | -76.82M |
| Net Income | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
Balance Sheet | |||||
| Total Assets | 219.57M | 108.93M | 64.00M | 64.21M | 79.59M |
| Cash, Cash Equivalents and Short-Term Investments | 191.40M | 97.72M | 52.23M | 52.15M | 45.02M |
| Total Debt | 24.97M | 23.05M | 5.40M | 7.63M | 9.38M |
| Total Liabilities | 60.35M | 64.90M | 49.18M | 37.45M | 37.22M |
| Stockholders Equity | 159.22M | 44.03M | 14.83M | 26.76M | 42.37M |
Cash Flow | |||||
| Free Cash Flow | -84.30M | -58.46M | -37.34M | -43.61M | -69.82M |
| Operating Cash Flow | -76.33M | -56.02M | -37.01M | -43.48M | -65.67M |
| Investing Cash Flow | 105.03M | -39.24M | 208.00K | -23.96M | 66.06M |
| Financing Cash Flow | 26.04M | 104.14M | 37.06M | 43.17M | 24.86M |
Abeona Therapeutics Technical Analysis
Positive
4.91
Price Trends
4.91
Positive
4.98
Negative
5.45
Negative
Market Momentum
>-0.01
Negative
54.70
Neutral
79.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Positive. The current price of 4.91 is above the 20-day moving average (MA) of 4.62, above the 50-day MA of 4.91, and below the 200-day MA of 5.45, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.70 is Neutral, neither overbought nor oversold. The STOCH value of 79.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABEO.
Abeona Therapeutics Risk Analysis
Abeona Therapeutics disclosed 48 risk factors in its most recent earnings report. Abeona Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abeona Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $280.11M | 3.92 | 53.18% | ― | ― | ― | |
47 Neutral | $762.02M | -0.19 | 72.70% | ― | ― | -1072.48% | |
44 Neutral | $270.65M | -6.10 | -300.94% | ― | ― | ― | |
44 Neutral | $143.29M | -3.72 | -424.76% | ― | ― | 82.23% | |
43 Neutral | $151.40M | -8.62 | 25.65% | ― | ― | 18.82% |
* Healthcare Sector Average
ABEO
Abeona Therapeutics
4.91
-0.04
-0.81%
GALT
Galectin Therapeutics
2.30
0.96
71.64%
SLN
Silence Therapeutics
5.73
3.02
111.44%
HUMA
Humacyte
0.65
-0.85
-56.71%
VOR
Vor Biopharma
15.47
1.65
11.94%
Abeona Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair
Positive
Apr 7, 2026
On April 7, 2026, Abeona Therapeutics announced that Keith A. Goldan had been appointed as an independent member of its Board of Directors, effective April 1, 2026, and as Chairman of the Audit Committee. With more than two decades of financial le...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
Neutral
Mar 20, 2026
On March 16, 2026, Abeona Therapeutics Inc.’s board approved Third Amended and Restated Bylaws, replacing bylaws last updated on July 9, 2024, to clarify rules around calling, postponing, rescheduling, or canceling annual and special shareho...
Business Operations and StrategyProduct-Related Announcements
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
Positive
Mar 9, 2026
Abeona Therapeutics said on March 9, 2026, that commercial momentum is building for ZEVASKYN, its FDA-approved autologous gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa, following optimization of a key release ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.